KYMR

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Kymera presented new preclinical lupus data for KT-579Jun 8, 2026
• Kymera Therapeutics presented new preclinical data for KT-579 in inflammatory bowel diseaseMay 5, 2026
• Kymera Therapeutics received FDA Fast Track designation for KT-621 for asthmaApr 13, 2026
• Kymera Therapeutics dosed first patient in BREADTH Phase 2b asthma trial of KT-621Jan 30, 2026
• Kymera Therapeutics receives FDA Fast Track for KT-621 oral STAT6 degrader in atopic dermatitisDec 11, 2025